Figure S7 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma

2026 Open access

Read full text
Authors: W. Frank Lenoir, Michael R. McKeown, Giulia Giorgetti, Marek J. Kobylarz, Tamara D. Hopkins, Wayne L. Glore, Michelle G. Shum, Yaretzi Calderón, Jessica Encinas, Luis A. Carvajal, Kameron R. Mori, Jun Li
+11 more Hua Gao, Yupeng Zheng, Zhihua Ma, Nikolaus D. Obholzer, Minyun Zhou, Benjamin Wesley Trotter, Christopher J. Dinsmore, Nikhil C. Munshi, Charles Y. Lin, Mariateresa Fulciniti, Peter B. Rahl
DOI: 10.1158/0008-5472.31345649
Cited by: 0

Abstract

Pharmacodynamics of p300 inhibitor combination with other mechanisms.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Chromatin Remodeling and Cancer

Publication details

Publication date
16 February 2026
Language
EN